Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats

Atherosclerosis

Volumn 127, Issue 1, 1996, Pages 91-101

  Krause, B R ^a   Barnett, B C ^a   Essenburg, A D ^a   Kieft, K A ^a   Auerbach, B J ^a   Bousley, R ^a   Stanfield, R ^a   Newton, R S ^a   Bisgaier, C L ^a  

^a PFIZER INC   (United States)

Author keywords

apolipoproteins; cholesterol; fibrates; lipoproteins; triglyceride

Indexed keywords

APOLIPOPROTEIN E; BEZAFIBRATE; CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; HUMAN; HYPERLIPIDEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BEZAFIBRATE; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; GEMFIBROZIL; HYPERTRIGLYCERIDEMIA; IMMUNOELECTROPHORESIS; LIPOPROTEIN LIPASE; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SPECTROPHOTOMETRY; TRIGLYCERIDES;

EID: 0030588654     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05939-4     Document Type: Article

References (67)

1. [1] Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987;83(suppl 5B):9.
2. [2] Shepherd J, Packard CJ. Pharmacological approaches to the modulation of plasma cholesterol. Trends Pharm Sci 1988;9:326.
3. [3] Gnasso A, Lehner B, Haberbosch W, Leiss O, von Bergmann K, Augustin J. Effect of gemfibrozil on lipids, apolipoprotein, and postheparin lipolytic activities in normolipidemic subjects. Metabolism 1986;35:387.
4. [4] Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, Type IIa, Type III and Type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987;79:1110.
5. [5] Simsolo RB, Ong JM, Kern PA. Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase. Metabolism 1993;42:1486.
6. [6] Vessby B. Lithell H, Ledermann H. Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridemic patients with bezafibrate. Atherosclerosis 1982;44:113.
7. [7] Neuman J, Neuman MP, Di Biase L. Effect of bezafibrate on low levels of high density lipoprotein cholesterol in normolipidemia. Arzneim Forsch 1986;36:1690.
8. [8] Nakandakare E, Garcia RC, Rocha JC, Sperotto G, Oliveira HCF, Quintao ECR. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis 1990;85:211.
9. [9] Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985;75:1702.
10. f 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 1984;74:2164.
11. [11] Kissebah AH, Alfarsi S, Adams PW, Seed M, Folkard J, Wynn V. Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apolipoprotein in patients with endogenous hypertriglyceridaemia. Effects of 2,2-dimethyl, 5(2,5-xylyloxy) valeric acid therapy. Atherosclerosis 1976;24:199.
12. [12] Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. J Am Med Assoc 1984;251:2241.
13. [13] Shepherd J, Caslake MJ, Lorimer AR, Vallance BD, Packard CJ. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 1985;5:162.
14. [14] Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins. J Am Med Assoc 1985;253:2398.
15. [15] Sirtori CR, Manzoni C, Lovati MR. Mechanisms of lipid-lowering drugs. Cardiology 1991;78:226.
16. [16] Strobl W, Gorder JL, Fienup GA, Lin-Lee Y, Gotto AM, Patsch W. Effect of sucrose diet on apolipoprotein synthesis in rat liver. Increase in apolipoprotein E gene transcription. J Biol Chem 1989;264:1190.
17. [17] Sloop CH, Krause BR. Portal and aortic blood sampling technique in unrestrained rats. Physiol Behav 1981;26:529.
18. [18] Bagdade JD, Yee E, Albers J, Pykalisto OJ. Glucocorticoids and triglyceride transport: effects on triglyceride secretion rates, lipoprotein lipase and plasma lipoproteins in the rat. Metabolism 1976;25:533.
19. [19] Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995;117:237.
20. [20] Kuusi T, Nikkila EA, Taskinen M-R, Somerharju P, Ehnholm C. Human postheparin plasma hepatic lipase activity against triacylglycerol and phospholipid substrates. Clin Chim Acta 1982;122:39.
21. [21] Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470.
22. [22] Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476.
23. [23] Kieft KA, Bocan TMA, Krause BR. Rapid determination of cholesterol distribution among plasma lipoproteins following high performance gel filtration chromatography. J Lipid Res 1991;32:859.
24. [24] Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966;15:45.
25. [25] Seishima M, Bisgaier CL, Davies SL, Glickman RM. Regulation of hepatic apolipoprotein synthesis in 17 α-ethinyl estradiol-treated rats. J Lipid Res 1991;32:941.
26. [26] Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol and total cholesterol in tissue lipid extracts. Clin Biochem 1993;26:39.
27. [27] Ott L. An Introduction to Statistical Methods and Data Analysis. Massachusetts: Duxbury Press, 1977;730.
28. [28] Buchanan JL, Sprancmanis V, Partyka RA. Hypocholesterolemic 5-substituted tetrazoles. J Med Chem 1969;12:1001.
29. [29] Moss JN, Dajani EZ. Antihyperlipidemic agents. In: Turner RA, Hebborn P (eds). Screening Methods in Pharmacology. New York: Academic Press, 1971;121.
30. [30] Nguyen LM, Niesor E, Bentzen CL. Gem-diphosphonate and gem-phospnate-phosphate compounds with specific high density lipoprotein inducing activity. J Med Chem 1987;30:1426.
31. [31] Dvornik D, Cayen MN. Drugs affecting lipoprotein disposition in laboratory animals. In: Fumagalli R, Kritchevsky, Paoletti R (eds). Drugs Affecting Lipid Metabolism. Amsterdam: Elsevier/ North-Holland Biomedical Press, 1980;263.
32. [32] Kusama H, Nishiyama M, Ikeda S. Pharmacological investigation of bezafibrate, a hypolipidemic agent. 1) Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Folia Pharmacol Jpn 1988;92:175.
33. [33] Alegret M, Ferrando R, Vazquez M, Adzet T, Merlos M, Laguna JC. Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br J Pharmacol 1994;112:551.
34. [34] Stahlberg D, Angelin B, Einarsson K. Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes. J Lipid Res 1989;30:953.
35. [35] Berndt J, Gaumert R, Still J. Mode of action of the lipid-lowering agents clofibrate and BM 15075 on cholesterol biosynthesis in rat liver. Atherosclerosis 1978;30:147.
36. [36] Kritchevsky D, Tepper SA, Story JA, Mueller DM, Klurfeld DM. Effect of bezafibrate on cholesterol metabolism in the rat. In: Greten H, Lang PD, Schettler G (eds). Lipoproteins and Coronary Heart Disease. New York: Gerhard Witzstrock Publishing House, 1980;92.
37. [37] Fukuda K, Shindo H, Yamashina S, Mizuhira V. Fine structural changes in the hepatic microbodies of rats treated with hypolipidemic agents, gemfibrozil and clofibrate. Acta Histochem Cytochem 1978;11:432.
38. [38] Pill J, Volkl A, Hartig F, Fahimi HD. Differences in the response of Sprague-Dawley and Lewis rats to bezafibrate: the hypolipidemic effect and the induction of peroxisomal enzymes. Arch Toxicol 1992;6:327.
39. [39] Malkonen M, Muona M, Manninen V. Studies on hypoxic dyslipidemia. Effect of lipid modulating drugs. Acta Med Scand 1982;668(Suppl):130.
40. [40] Staels B, van Tol A, Andreu T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 1991;11:760.
41. [41] Mahley RW. Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin N Am 1982;66:375.
42. [42] Krause BR, Newton RS. Gemfibrozil increases both apo AI and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats. Atherosclerosis 1986;59:95.
43. [43] Tam S-P. Effects of gemfibrozil and ketoconazole on human apolipoprotein AI, B and E levels in two hepatoma cell lines, HepG2 and Hep3B. Atherosclerosis 1991;91:51.
44. [44] Morrisett JD, Kim H-S, Patsch JR, Datta SK, Trentin JJ. Genetic susceptibility and resistance to diet-induced atherosclerosis and hyperlipoproteinemia. Arteriosclerosis 1982;2:312.
45. [45] Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apo lipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343.
46. [46] Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apo lipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992;89:4471.
47. [47] Saxena U, Ferguson E, Bisgaier CL. Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix. J Biol Chem 1993;268:14812.
48. [48] Auerbach BJ, Bisgaier CL, Wolle J, Saxena U. Oxidation of low density lipoproteins greatly enhances their association with lipoprotein lipase anchored to endothelial cell matrix. J Biol Chem 1996;271:1329.
49. [49] Kazumi T, Yoshino G, Iwai M et al. Long-term effects of bezafibrate on the in vivo VLDL-triglyceride production in the rat. Diabetes Res Clin Pract 1990;9:163.
50. [50] D'Costa MA, Smigura FC, Kulhay K, Angel A. Effects of clofibrate on lipid synthesis, storage and plasma Intralipid clearance. J Lab Clin Med 1977;90:823.
51. [51] Staels B, Peinado-Onsurbe J, Auwerx J. Down-regulation of hepatic lipase gene expression and activity by fenofibrate. Biochim Biophys Acta 1992;1123:227.
52. [52] Fan J, Wang J, Bensadoun A et al. Overproduction of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci 1994;91:8724.
53. [53] Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart J-C, Dallongeville J, Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. J Clin Invest 1995;95:705.
54. [54] Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. J Biol Chem 1995;270:13470.
55. [55] Haubenwallner S, Essenburg AD, Barnett BC et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995;36:2541.
56. [56] Sloop CH, Dory L, Hamilton R, Krause BR and Roheim PS. Characterization of dog peripheral lymph lipoproteins: The presence of a disc-shaped 'nascent' HDL. J Lipid Res 1983;24:1429.
57. [57] Krause BR, Newton RS. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats. J Lipid Res 1985;26:940.
58. [58] Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979;575:266.
59. [59] Krause BR, Bousley R, Kieft K, Robertson D, Stanfield R, Urda E, Newton RS. Comparison of lifibrol to other lipid-regulating agents in experimental animals. Pharm Res 1994;29:345.
60. [60] Krause BR, Anderson M, Bisgaier CL et al. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res 1993;34:279.
61. [61] Bon B, Cazzolato G, Saccardi M, Kostner GM, Avogaro P. Total plasma apo E and high density lipoprotein apoE in survivors of myocardial infarction. Atherosclerosis 1984;53:69.
62. [62] Yamashita S, Sprecher DL, Sakai N, Matsuzawa Y, Tarui S, Hui DY. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest 1990;86:688.
63. [63] Bisgaier CL, Siebenkas MV, Brown ML et al. Familial cholesteryl ester protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. J Lipid Res 1991;32:21.
64. [64] Gambert P, Farnier M, Girardot G, Brun J-M, Lallemant C. Effects of gemfibrozil on serum apolipoprotein E distribution in hypercholesterolemic patients. Atherosclerosis 1991;89:267.
65. [65] Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Eng J Med 1987;317:1237.
66. [66] Cayen MN. Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharm Ther 1985;29:157.
67. [67] Sirtori CR, Franceschini G, Gianfranceschi G et al. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. J Lab Clin Med 1987;110:279.